INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $1,283 | +36.3% | 17,910 | -0.9% | 0.03% | +40.9% |
| Q3 2023 | $941 | -20.5% | 18,073 | -3.3% | 0.02% | -8.3% |
| Q2 2023 | $1,183 | +5.8% | 18,688 | -9.5% | 0.02% | -7.7% |
| Q1 2023 | $1,118 | +11.0% | 20,639 | +8.4% | 0.03% | -10.3% |
| Q4 2022 | $1,007 | -99.9% | 19,033 | -2.4% | 0.03% | +20.8% |
| Q3 2022 | $907,000 | -20.9% | 19,500 | -3.0% | 0.02% | -31.4% |
| Q2 2022 | $1,147,000 | -9.6% | 20,095 | -3.1% | 0.04% | +20.7% |
| Q1 2022 | $1,269,000 | +21.9% | 20,733 | +4.2% | 0.03% | +26.1% |
| Q4 2021 | $1,041,000 | +31.4% | 19,897 | -6.4% | 0.02% | +35.3% |
| Q3 2021 | $792,000 | -6.7% | 21,250 | +2.2% | 0.02% | -10.5% |
| Q2 2021 | $849,000 | +24.9% | 20,789 | +3.7% | 0.02% | +26.7% |
| Q1 2021 | $680,000 | -13.7% | 20,047 | -19.1% | 0.02% | 0.0% |
| Q4 2020 | $788,000 | -5.7% | 24,775 | -23.9% | 0.02% | -31.8% |
| Q3 2020 | $836,000 | +45.1% | 32,565 | +45.1% | 0.02% | +29.4% |
| Q2 2020 | $576,000 | +73.0% | 22,438 | +3.6% | 0.02% | +30.8% |
| Q1 2020 | $333,000 | -67.6% | 21,668 | -27.8% | 0.01% | -23.5% |
| Q4 2019 | $1,029,000 | +244.1% | 30,000 | -25.0% | 0.02% | +142.9% |
| Q3 2019 | $299,000 | -54.8% | 40,000 | -21.6% | 0.01% | -58.8% |
| Q2 2019 | $662,000 | +81.4% | 51,000 | +70.0% | 0.02% | +88.9% |
| Q1 2019 | $365,000 | +6.7% | 30,000 | 0.0% | 0.01% | -35.7% |
| Q4 2018 | $342,000 | -73.8% | 30,000 | -50.2% | 0.01% | -60.0% |
| Q3 2018 | $1,306,000 | -1.4% | 60,205 | -19.7% | 0.04% | +9.4% |
| Q2 2018 | $1,325,000 | -33.8% | 75,000 | -21.1% | 0.03% | -49.2% |
| Q1 2018 | $2,000,000 | +31.6% | 95,000 | -9.5% | 0.06% | +61.5% |
| Q4 2017 | $1,520,000 | -8.0% | 105,000 | +0.3% | 0.04% | -36.1% |
| Q3 2017 | $1,652,000 | +14.6% | 104,700 | -9.7% | 0.06% | 0.0% |
| Q2 2017 | $1,441,000 | +10.8% | 116,000 | +45.0% | 0.06% | +17.3% |
| Q1 2017 | $1,300,000 | -52.1% | 80,000 | -55.6% | 0.05% | -60.6% |
| Q4 2016 | $2,716,000 | +1086.0% | 180,000 | +1100.0% | 0.13% | +842.9% |
| Q3 2016 | $229,000 | -87.5% | 15,000 | -68.3% | 0.01% | -90.1% |
| Q2 2016 | $1,839,000 | -57.7% | 47,385 | -69.7% | 0.14% | -24.9% |
| Q1 2016 | $4,351,000 | -29.0% | 156,500 | +37.3% | 0.19% | -55.2% |
| Q4 2015 | $6,132,000 | +34.3% | 114,000 | 0.0% | 0.42% | +108.9% |
| Q3 2015 | $4,565,000 | +614.4% | 114,000 | +470.0% | 0.20% | +708.0% |
| Q2 2015 | $639,000 | -66.5% | 20,000 | -75.0% | 0.02% | -70.6% |
| Q1 2015 | $1,910,000 | +333.1% | 80,000 | +220.0% | 0.08% | +466.7% |
| Q4 2014 | $441,000 | -44.5% | 25,000 | -56.9% | 0.02% | -21.1% |
| Q3 2014 | $794,000 | -18.7% | 57,945 | 0.0% | 0.02% | -9.5% |
| Q2 2014 | $977,000 | – | 57,945 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 156,250 | $8,268,750 | 5.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 221,856 | $11,733,964 | 3.62% |
| Vahanian & Associates Financial Planning Inc. | 18,592 | $983,889 | 3.22% |
| Altium Capital Management LP | 100,000 | $5,292,000 | 2.69% |
| Bellevue Group AG | 3,342,236 | $176,871,129 | 2.35% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,036,948 | $54,875,288 | 2.30% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 140,366 | $7,428,169 | 2.12% |
| Nicholas Investment Partners, LP | 413,507 | $21,882,790 | 1.92% |
| TANG CAPITAL MANAGEMENT LLC | 240,000 | $12,700,800 | 1.84% |
| Octagon Capital Advisors LP | 220,953 | $11,692,833 | 1.82% |